Undiagnosed hyperglycemia in patients treated with atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 66, Issue 11, 2005, Pages 1463-1467

  Sernyak, Michael J ^a,b   Gulanski, Barbara ^a,b   Rosenheck, Robert ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; COMORBIDITY; DIABETES MELLITUS; DIET RESTRICTION; ETHNIC DIFFERENCE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; OUTPATIENT; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZATION;

EID: 28844492198     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n1117     Document Type: Article

References (23)

1. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443
2. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783
3. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;111:716-723
4. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-852
5. Koller E, Cross J, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735-744
6. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-863
7. Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-930
8. Wirshing DA, Boyd JR, Meng LS, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865
9. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with the use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566
10. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the third national health and nutrition examination survey, 1988-1994. Diabetes Carel998;21:518-524
11. Sernyak MJ, Gulanski B, Leslie DL, et al. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry 2003;64:605-608
12. Rosenheck R, Leslie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care 2001;39:302-308
13. Glucose performed on the Olympus 640, VA Connecticut Healthcare System; 2001. Manual for Olympus AU640 Chemistry Analyzer. Olympus Optical Co., Ltd., Tokyo, Japan
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(suppl 1):S5-10
15. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 2001;322:15-18
16. Fisman EZ, Motro M, Tenenbaum A, et al. Impaired fasting glucose concentrations in nondiabetic patients with ischeic heart disease: a marker for a worse prognosis. Am Heart J 2001;141:485-490
17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
18. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(suppl 27):15-26
19. Luna B, Feinglos M. Drug-induced hyperglycemia. JAMA 2001;286:1945-1948
20. Susce MT, Villanueva N, Diaz FJ, et al. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 2005;66:167-173
21. Marder SR, Essock SM, Miller A, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-1349
22. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
23. VA Pharmacy Benefits Management Strategic Healthcare Group and Medical Advisory Panel. Antipsychotics and Metabolic Effects: 2002-2003 Update. Available at: http://www.vapbm.org/PBM/ treatment.htm. Accessed February 22, 2005